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ABSTRACT
The histone deacetylase 6 (HDAC6) plays critical roles in human tumorigenesis 
and metastasis. As such, HDAC6-selective inhibitors have entered clinical trials for 
cancer therapy. However, the upstream regulator(s), especially ubiquitin E3 ligase(s), 
responsible for controlling the protein stability of HDAC6 remains largely undefined. 
Here, we report that Cullin 3SPOP earmarks HDAC6 for poly-ubiquitination and degradation. 
We found that the proteasome inhibitor MG132, or the Cullin-based E3 ligases inhibitor 
MLN4924, but not the autophagosome-lysosome inhibitor bafilomycin A1, stabilized 
endogenous HDAC6 protein in multiple cancer cell lines. Furthermore, we demonstrated 
that Cullin 3-based ubiquitin E3 ligase(s) primarily reduced the stability of HDAC6. 
Importantly, we identified SPOP, an adaptor protein of Cullin 3 family E3 ligases, 
specifically interacted with HDAC6, and promoted its poly-ubiquitination and subsequent 
degradation in cells. Notably, cancer-derived SPOP mutants disrupted their binding with 
HDAC6 and thereby failed to promote HDAC6 degradation. More importantly, increased 
cellular proliferation and migration in SPOP-depleted HCT116 colon cancer cells could 
be partly reversed by additional depletion of HDAC6, suggesting that HDAC6 is a key 
downstream effector for SPOP tumor suppressor function. Together, our data identify 
the tumor suppressor SPOP as an upstream negative regulator for HDAC6 stability, and 
SPOP loss-of-function mutations might lead to elevated levels of the HDAC6 oncoprotein 
to facilitate tumorigenesis and metastasis in various human cancers.
INTRODUCTION
Histone acetyltransferases (HATs) and their 
counteracting enzymes, histone deacetylases (HDACs) 
are the Yin and Yang forces that govern tumor initiation, 
progression, and metastasis largely through the acetylation 
and deacetylation of histone and non-histone proteins 
[1]. Currently, 18 potential human HDACs have been 
reported and grouped into four classes based on their 
sequence identity, catalytic mechanisms, and homology 
with yeast histone deacetylases [1, 2]. Specifically, 
Rpd3-like deacetylases (Class I) consist of four different 
isoforms: HDAC1, 2, 3, and 8. Hda1-like enzymes (Class 
II) with six isoforms are further divided into Class IIa 
(HDAC4, 5, 7, 9) and Class IIb (HDAC6 and 10). Sir2-
like deacetylases (Class III) are comprised of seven 
NAD+-dependent sirtuins: Sirt1-7. Finally, HDAC11 is the 
only known member of the Class IV. As the expression 
and function of HDACs are frequently dysregulated in 
multiple types of human cancers, targeting HDACs has 
become a promising therapeutic option for cancer therapy. 
To this end, many HDACs inhibitors have been developed 
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for clinical use with four having been approved thus far 
by the FDA, notably vorinostat, romidepsis, panobinostat 
and belinostat. However, these pan-HDAC inhibitors 
which are largely able to inhibit Class I, II and IV enzymes 
have severe side-effects which limit their prolonged use 
for cancer therapy. Recently, molecules targeting specific 
HDAC isoforms have been designed and investigated [3]. 
Notably, the HDAC6 stands apart from the rest of HDACs 
because of its unique structure and physiological functions 
in cells [4, 5].
HDAC6 is a unique member of HDACs due to 
the fact that it contains two functional catalytic domains 
and has many non-histone protein targets, such as 
tubulin [6], HSP90 [7], cortactin [8] and p53 [9]. Hence, 
HDAC6 is involved in regulating diverse key biological 
processes including cell motility, cell division, protein 
trafficking, and apoptosis largely through changing the 
acetylation status of its target proteins [10, 11]. Moreover, 
dysregulation of HDAC6 enzymatic activity has been 
reported to associate with various human diseases 
including cancers and neurological diseases. Indeed, 
overexpression of HDAC6 can promote tumorigenesis, 
invasion, and metastasis [5, 11]. Therefore, these unique 
features of HDAC6 have made it an interesting potential 
therapeutic target and HDAC6 specific inhibitors have 
entered into preclinical and clinical development [5, 
10, 11]. Although HDAC6 activity is regulated by 
posttranslational modifications, such as phosphorylation 
by Aurora A kinase [12] and extracellular signal-regulated 
kinase (ERK) [13], or acetylation by p300 [14], the 
upstream regulator(s), especially ubiquitin E3 ligase(s), 
regulating the HDAC6 protein stability have not yet been 
fully elucidated.
The Cullin-Ring ligases (CRLs) are the largest 
family of E3 ubiquitin ligases and are categorized into 
seven subfamilies based on Cullin scaffold proteins 
(Cullin1, 2, 3, 4A, 4B, 5 and 7) [15, 16]. Recently, the 
CRL3 subfamily of E3 ubiquitin ligases have been linked 
to various human diseases, such as neurodegeneration 
and cancer [17]. Like other CRLs family complexes, 
CRL3 consists of a Cullin scaffold protein (Cullin 3), 
the RING protein Rbx1, and a variable BTB domain 
adaptor protein, which serves as a substrate recognition 
component to recruit protein substrates into the complex 
for ubiquitination [17]. The Speckle-type POZ (pox virus 
and zinc finger protein) protein (SPOP) is a CRL3 family 
adaptor protein,which comprises two conserved functional 
domains: an N-terminal meprin and TRAF homology 
(MATH) domain that is primarily involved in substrate 
recognition and a C-terminal bric-a-brac, tramtrack and 
broad complex (BTB)/POZ domain that binds Cullin 3 
to form a functional multi-component E3 ligase complex 
(Cullin 3SPOP) [18].
In this study, we report that Cullin 3SPOP is a bona 
fide E3 ubiquitin ligase for HDAC6, which functions to 
earmark HDAC6 for poly-ubiquitination and subsequent 
degradation. Importantly, cancer-derived SPOP mutations 
disrupt their binding with HDAC6 and are thereby deficient 
in promoting HDAC6 destruction. Physiologically, 
depletion of SPOP could increase the cellular proliferation 
and migration, which could be partly reversed by 
additional depletion of HDAC6. These findings provide the 
molecular insights into how loss of SPOP function may be 
mechanistically linked with elevated HDAC6 protein levels 
that may facilitate tumorigenesis and metastasis in cancer 
patients with SPOP-mutant genetic status.
RESULTS
The ubiquitin proteasome system, but not 
autophagosome-lysosome, controls the protein 
stability of HDAC6 in cells
The ubiquitin proteasome system and the 
autophagosome-lysosome are two major pathways that 
regulate protein degradation in cells. MG132 is a peptide 
aldehyde (Z-Leu-Leu-Leu-al) that selectively blocks 
the proteolytic activity of the 26S proteasome to reduce 
the degradation of ubiquitin-conjugated proteins in 
mammalian cells [19]. MLN4924 is a specific inhibitor of 
the NEDD8-activating enzyme (NAE), which inactivates 
CRL containing E3 ubiquitin ligases through inhibiting 
Cullin neddylation [20], thereby stabilizing downstream 
substrates of various CRLs [21]. Importantly, we found 
that both MG132 and MLN4924 treatment stabilized 
HDAC6 at the endogenous level in multiple cancer cell 
lines including HT29 (Figure 1A-1B and Supplementary 
Figure 1A), HCT116 (Figure 1C-1D and Supplementary 
Figure 1B), and HeLa (Figure 1E). In addition to the 
ubiquitin proteasome system, the autophagosome-
lysosome is another important pathway involved in 
regulating protein degradation in cells (Supplementary 
Figure 1C). To explore whether HDAC6 stability is also 
controlled by the autophagosome-lysosome, we utilized 
the well-characterized bafilomycin A1 inhibitor to block 
the autophagosome-lysosome pathway [22, 23]. Notably, 
although bafilomycin A1 treatment could dramatically 
elevated the protein abundance of LC3B-II, a biomarker 
of autophagy, it did not lead to significant changes of 
HDAC6 protein level in various cancer cell lines including 
HCT116 (Figure 1F), DLD1 (Supplementary Figure 1D), 
and HeLa cells (Supplementary Figure 1E). Together, 
these results suggest that the ubiquitin proteasome system, 
but not autophagosome-lysosome, might control the 
protein stability of HDAC6 in cells.
HDAC6 protein stability is negatively regulated 
by the Cullin 3 family of E3 ubiquitin ligases
Our results showed that in addition to MG132, 
MLN4924 could also stabilize endogenous HDAC6 
protein, indicating that the Cullin-Ring family of E3 
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ligase(s) might be responsible to regulate HDAC6 protein 
stability. To identify which member of the Cullin-based E3 
ubiquitin ligases governs the protein stability of HDAC6, 
we screened the interaction of Cullin family members 
with HDAC6 and found that Cullin 1 and Cullin 3, but 
not the other Cullin family members including Cullin 2, 
Cullin 4A, Cullin 4B, Cullin 5, and Cullin 7, interacted 
with HDAC6 in cells (Figure 2A). However, depletion of 
Cullin 3, but not Cullin 1, elevated the protein abundance 
of endogenous HDAC6 in multiple cancer cell lines 
including HT29 (Figure 2B-2C), HCT116 (Figure 2D-
2E), PC3 (Supplementary Figure 2A-2B), and HeLa 
(Supplementary Figure 2C). These results therefore 
indicate that only Cullin 3, but not Cullin 1, subfamily of 
E3 ligases, primarily regulates HDAC6 protein stability 
in cells. In keeping with this notion, depletion of Cullin 
3 prolonged the half-life of HDAC6 in cells (Figure 2F-
2G). These results together reveal that Cullin 3-based 
E3 ubiquitin ligase(s) plays a crucial role in regulating 
HDAC6 protein stability in cells.
SPOP, but not other Cullin 3 family of adaptor 
proteins, specifically interacts with and promotes 
HDAC6 poly-ubiquitination and degradation
Cullin 3-based E3 ubiquitin ligase(s) utilize one 
of several adaptor proteins with a BTB/POZ domain to 
recognize its downstream ubiquitin substrates [17]. To 
further explore which adaptor protein of Cullin 3-based 
E3 ubiquitin ligases promotes the poly-ubiquitination 
and degradation of HDAC6, we examined the interaction 
of HDAC6 with a panel of BTB domain containing 
adaptor proteins and found that SPOP, but not other 
Cullin 3-based E3 ligase adaptor proteins including 
Keap1, KLHL2, KLHL3, KLHL12, KLHL37, or PLZF 
interacted with HDAC6 (Figure 3A, Supplementary 
Figure 3A). Moreover, ectopic expression of SPOP, but 
not Keap1 nor COP1, dramatically decreased the protein 
abundance of HDAC6 in cells (Figure 3B). Notably, 
ectopic expression of SPOP reduced HDAC6 protein 
levels in a dose-dependent manner at both the exogenous 
or endogenous levels (Figure 3C-3D). Furthermore, 
depletion of SPOP using several independent shRNAs 
elevated the endogenous HDAC6 protein abundance in 
multiple cancer cell lines including HCT116 (Figure 3E), 
DU145 (Figure 3F), PC3 (Supplementary Figure 3B), 
and HeLa (Supplementary Figure 3C). In keeping with 
the notion that SPOP negatively regulates the protein 
stability of HDAC6, compared with shScramble-treated 
cells, the half-life of endogenous HDAC6 was prolonged 
in shSPOP-treated cells (Figure 3G-3H). Consistently, 
ectopic expression of SPOP could significantly promote 
the poly-ubiquitination of HDAC6 in cells (Figure 3I). 
Taken together, these results demonstrate that the Cullin 
Figure 1: The ubiquitin proteasome system, but not autophagosome-lysosome, controls the protein stability of HDAC6 
in cells. (A-B) Immunoblot (IB) analysis of whole cell lysates (WCLs) derived from HT29 cells treatment with 10 μM, 20 μM MG132 (A) 
or 1 μM, 2 μM MLN4924 (B) for 12 hours before harvesting. (C-D) IB analysis of WCLs derived from HCT116 cells treatment with 10 
μM, 20 μM MG132 (C) or 1 μM, 2 μM MLN4924 (D) for 12 hours before harvesting. (E) IB analysis of WCLs derived from HeLa cells 
treatment with 10 μM or 20 μM MG132 before harvesting. (F) IB analysis of WCLs derived from HCT116 cells treatment with/without 
100 nM Bafilomycin A1 (Baf-A1) at indicated time course before harvesting.
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3SPOP E3 ubiquitin ligase complex is an upstream negative 
regulator that promotes poly-ubiquitination and subsequent 
degradation of HDAC6.
Deletion of the degron motif in HDAC6 confers 
resistance to SPOP-mediated degradation
Previous studies from us and other groups have 
identified that SPOP substrates including Ci/Gli [24], 
Daxx [25], MacroH2A [26], ERG [27, 28], AR [29, 30], 
PTEN [31] SRC-3 [32], DEK [33], TRIM24 [33], Cdc20 
[34] and EglN2 [35] share a SPOP-binding motif Φ-Π-S-
S/T-S/T (Φ-nonpolar; Π, polar amino acid) (Figure 4A) 
[18]. Through examining the protein sequence of HDAC6, 
we found two putative SPOP motifs, or “degrons” in 
HDAC6: 7DSTTT11 (termed degron 1) and 843GPSSS847 
(termed degron 2) (Figure 4A). To identify which degron 
is required for SPOP-mediated degradation of HDAC6, 
we generated HDAC6 mutants with deletion of each 
individual degron and found that HDAC6 harboring 
deletion of degron 2 (ΔD2), but not degron 1 (ΔD1), 
became largely resistant to SPOP-mediated HDAC6 
degradation (Figure 4B). Consistently, compared to WT 
or ΔD1 mutant, the HDAC6-ΔD2 mutant lost its ability 
to bind with SPOP and exhibited an extended half-life in 
cells (Figure 4C-4E). Furthermore, HDAC6 with ΔD2 
mutant, but not the ΔD1 mutant, became resistant to 
SPOP-mediated poly-ubiquitination in cells (Figure 4F). 
These results together demonstrate that the degron 2 motif 
843GPSSS847 is required for SPOP to recognize and promote 
the poly-ubiquitination and subsequent degradation of 
HDAC6 in cells.
Cancer-associated SPOP mutants fail to interact 
with and promote the degradation of HDAC6
Previous studies have shown that SPOP is mutated 
in many human cancers including prostate cancer, 
Figure 2: HDAC6 protein stability is negatively regulated by the Cullin 3 family E3 ligase. (A) IB analysis of WCLs and 
immunoprecipitates (IP) derived from 293T cells transfected with Flag-HDAC6 and Myc-Cullins constructs as indicated and treated with 
10 μM MG 132 before harvesting. (B-C) IB analysis of WCLs derived from HT29 cells infected with the indicated lentiviral shCullin 3 
(B) or shCullin 1 (C), respectively. (D-E) IB analysis of WCLs derived from HCT116 cells infected with the indicated lentiviral shRNAs 
against Cullin 3 (D) or Cullin 1 (E), respectively. (F-G) IB analysis of WCLs derived from HT29 cells stably infected with the indicated 
lentiviral shRNAs and treated with 100 μg/ml cycloheximide (CHX) for indicated times (F). Quantification of the band intensities of (F) 
using the ImageJ software (G). HDAC6 immunoblot bands were normalized to Vinculin, then normalized to the t = 0 time point.
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endometrial cancer, colorectal cancer, gastric cancer, 
and thyroid follicular tumors [36-40]. Interestingly, most 
SPOP mutations identified in human prostate cancers, 
such as Y87C, F102C, W131G, and F133L, are located in 
the MATH domain of SPOP, which presumably impairs 
its ability to bind to and recruit substrates into the Cullin 
3SPOP complex (Figure 5A). In keeping with this notion, 
we found that SPOP with the deletion of MATH domain 
failed to interact with HDAC6 in cells (Figure 5B). To 
explore whether these cancer-derived SPOP mutants also 
affects their interaction with HDAC6, we performed GST 
pull-down assays and found that SPOP mutants including 
Y87C, F102C, W131G, F133L, or F133V, but not SPOP 
WT, failed to interact with HDAC6 (Figure 5C). To 
further determine how these cancer-derived mutations 
affect endogenous HDAC6 abundance, we generated 
a melanoma cell line (WM2664) stably expressing 
SPOP WT or cancer-derived mutants including F102C, 
W131G, F133L, as well as empty vector (EV) as a 
negative control. Notably, compared to SPOP WT, 
cancer-derived SPOP mutants failed to decrease the 
protein abundance of endogenous HDAC6 in cells 
Figure 3: SPOP, but not other Cullin 3 family adaptor proteins, specifically interacts with and promotes HDAC6 
poly-ubiquitination and degradation. (A) IB analysis of WCLs and IP derived from 293T cells transfected with HA-HDAC6 and 
Flag-tagged Cullin 3 family adaptor constructs as indicated and treated with 10 μM MG132 for 12 hours before harvesting. (B-C) IB 
analysis of WCL derived from 293 (B) or 293T (C) cells transfected with indicated constructs. (D) IB analysis of WCL derived from HT29 
cells transfected with indicated constructs. (E-F) IB analysis of WCL derived from HCT116 (E) or DU145 (F) infected with the indicated 
lentiviral shRNAs against SPOP and subjected to puromycin selection for 72 hours before harvesting. (G-H) IB analysis of WCL derived 
from HeLa cells stably infected with the indicated lentiviral shRNAs against SPOP and treated with 100 μg/ml CHX for indicated times 
(G). Quantification of the band intensities of (G) using the ImageJ software (H). HDAC6 immunoblot bands were normalized to Vinculin, 
then normalized to the t = 0 time point. (I) IB of WCL and His pull-down from HCT116 cells transfected with the indicated constructs. Cells 
were treated with 30 μM MG132 for 6 hours and lysed with denature buffer.
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(Figure 5D). In keeping with these findings, we further 
found that ectopic expression of SPOP WT, but not 
cancer-derived mutants, could promote the degradation 
of HDAC6 in cells in a dose-dependent manner (Figure 
5E), which largely was due to deficiency in promoting 
the poly-ubiquitination of HDAC6 in cells (Figure 5F). 
These results demonstrate that cancer-derived mutations 
of SPOP in the MATH domain are unable to bind 
and promote the poly-ubiquitination and subsequent 
degradation of its downstream substrates including the 
HDAC6 oncoprotein, which might subsequently promote 
tumorigenesis.
Depletion of SPOP enhances the cellular 
proliferation and migration, which can be 
reversed partly by additional depletion of 
HDAC6 in colon cancer cells
HDAC6 plays an important role in tumorigenesis, 
invasion and metastasis [5, 11], whereas SPOP has been 
shown to be a well-characterized tumor suppressor [36-
40]. We therefore hypothesized that SPOP exerts its 
tumor suppressor function partly through regulating 
the stability of HDAC6 oncoprotein. The epithelial-
mesenchymal transition (EMT) is an important process 
Figure 4: Deletion of the degron motif in HDAC6 confers resistance to SPOP-mediated degradation. (A) Sequence 
comparison of HDAC6 with the putative SPOP binding motif (degron) with other known SPOP substrates, and a schematic illustration 
of HDAC6. NLS: Nuclear localization signal, NES: Nuclear export signal, CD: Catalytic domain, SET14: Cytoplasmic retention domain, 
UBP: Ubiquitin binding domain. (B) IB analysis of WCLs derived from 293T cells transfected with indicated constructs. (C) IB analysis of 
WCL and GST pull-down products derived from 293T cells transfected with indicated constructs. Cells were treated with 10 μM MG132 
for 12 hours before harvesting. (D-E) IB analysis of WCL derived from 293T cells transfected with indicated Flag-HDAC6 plasmids 
and treated for indicated times with 100 μg/ml CHX before harvesting (D). Quantification of the band intensities of (D) using the ImageJ 
software (E). HDAC6 immunoblot bands were normalized to Vinculin, then normalized to the t = 0 time point. (F) IB of WCL and His 
pull-down from HCT116 cells transfected with the indicated constructs. Cells were treated with 30 μM MG132 for 6 hours and lysed with 
denature buffer.
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during tumorigenesis and metastasis by which the 
epithelial cells acquire mesenchymal properties and show 
reduced intercellular adhesion and increased motility 
[41]. Previous studies have demonstrated that HDAC6 
could induce the EMT in cancer cells [42-45]. To this end, 
we further explore whether SPOP can regulate the EMT 
largely through governing the stability of HDAC6. Indeed, 
we found that depletion of SPOP promotes the EMT by 
decreasing the epithelial marker, E-cadherin and increasing 
the mesenchymal markers including vimentin, slug and 
snail (Figure 6A). However, additional depletion of 
HDAC6 abrogated the changes in EMT markers observed 
in cells with depletion of SPOP (Figure 6A), suggesting 
that SPOP regulates the EMT largely through controlling 
the stability of HDAC6. Furthermore, depleting SPOP 
in HCT116 cells led to elevated cellular proliferation 
(Figure 6B–6C) and migration (Figure 6D–6G) in vitro, 
which could be largely reversed by additional depletion of 
HDAC6 (Figure 6B–6G). These results together support 
the model that the tumor suppressor SPOP suppresses 
cellular proliferation and migration largely through 
negatively regulating the stability of HDAC6 oncoprotein.
DISCUSSION
In this study, we identified that Cullin 3SPOP is a bona 
fide E3 ubiquitin ligase for HDAC6. Our results showed 
that MLN4924, an inhibitor for Cullin-based E3 ligase, 
could stabilize HDAC6 in cells, which indicated that 
Cullin family E3 ligase might control HDAC6 protein 
stability (Figure 1). Indeed, HDAC6 could interact with 
Cullin 1 and Cullin 3, but not other members of Cullin 
family. However, depletion of Cullin 3, but not Cullin 
1, elevated the protein abundance of HDAC6 at the 
endogenous level, which suggested that only Cullin 
3-based E3 ligase primarily governs the protein stability 
of HDAC6 in cells (Figure 2). However, additional 
investigation is warranted to further understand the 
biological context of the interaction between Cullin 1 
and HDAC6 in cells. Furthermore, we identified SPOP as 
an adaptor protein of Cullin 3 that specifically binds to 
and promotes the poly-ubiquitinaion and degradation of 
HDAC6 in a degron-dependent manner (Figures 3 and 4). 
Although the mRNA levels of HDAC6 upon depletion 
of SPOP were not examined, we performed the half-life 
assays using cycloheximide to inhibit protein translation 
and found that depletion of SPOP could prolong the 
half-life of HDAC6 in cells, which indicated that Cullin 
3SPOP negatively regulate the stability of HDAC6 largely 
through the posttranslational modification. Importantly, 
cancer-derived SPOP mutations disrupted the binding 
between SPOP and HDAC6 and failed to promote HDAC6 
poly-ubiquitination and subsequently degradation (Figure 
5), which might lead to elevated levels of HDAC6 to 
Figure 5: Cancer-associated SPOP mutants fail to interact with and promote the degradation of HDAC6 in cells. 
(A) A schematic illustration of SPOP with MATH and BTB domain and cancer-associated mutations. (B) Immunoblot (IB) analysis of 
whole cell lysates (WCL) and immunoprecipitates (IP) derived from HeLa cells transfected with indicated plasmids and treated with 10 
μM MG132 before harvesting. (C) IB analysis of WCLs and GST pull-down products derived from 293T cells transfected with indicated 
constructs. (D) IB analysis of WCL derived from melanoma WM2664 cells stably expressed with SPOP WT and SPOP mutants. (E) IB 
analysis of WCL derived from 293T cells transfected with indicated constructs. (F) IB of WCL and His pull-down from HCT116 cells 
transfected with the indicated constructs. Cells were treated with 30 μM MG132 for 6 hours and lysed with denature buffer.
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promote tumorigenesis. Functionally, we demonstrated 
that the tumor suppressor SPOP suppresses the cancer 
cell proliferation and migration partly through negatively 
regulating the stability of HDAC6 (Figure 6).
A previous study has reported that the E3 ubiquitin 
ligase CHIP interacted with HDAC6 and promoted its 
poly-ubiquitination to suppress abnormal accumulation 
of the microtubule-binding protein tau, which was 
Figure 6: Depletion of SPOP enhances the cellular proliferation and migration, which can be reversed partly by 
additional depletion of HDAC6 in colon cancer cells. (A) Immunoblot (IB) analysis of whole cell lysates (WCL) derived from 
HCT116 infected with the indicated lentiviral shRNAs against SPOP and HDAC6, and subjected to puromycin selection for 72 hours 
before harvesting. (B) Colony formation assay using HCT116 cells described in Figure 6A. (C) Quantification of colony number of colony 
formation assays described in Figure 6B. Data were shown as mean ± SD from three independent experiments. *p < 0.05. (D) In vitro 
scratch assay at 0 and 48 hours using HCT116 cells described in Figure 6A. (E) Quantification of gap closure of in vitro scratch assay 
described in Figure 6D. Data were shown as mean ± SD from three independent experiments. *p < 0.05. (F) Representative images of 
migrated HCT116 cells described in Figure 6A in migration assays. (G) Quantification of migrated cells described in Figure 6F. Data were 
shown as mean ± SD of three independent experiments. *p < 0.05.
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correlated with cognitive decline in Alzheimer’s disease 
[46]. Here, our results demonstrated that the ubiquitin E3 
ligase Cullin 3SPOP also regulates HDAC6 stability largely 
through promoting its poly-ubiquitination and subsequent 
degradation. Hence, it remains unclear how these two 
different E3 ubiquitin ligases, Cullin 3SPOP and CHIP, 
respectively, regulate HDAC6 stability. It is plausible that 
each E3 ubiquitin ligase is working in different cellular 
contexts, leading to their regulating HDAC6 in the context 
of cancer (SPOP) or Alzeimer’s disease (CHIP) to impact 
different biological processes that warrants further in-
depth investigation.
Given its characterized oncogenic role, HDAC6 has 
become a promising drug target to treat human cancers, 
and several HDAC6 specific inhibitors have entered into 
clinical trials, such as ACY-1215 and ACY-241 [4, 5, 
47, 48]. Our results showed that prostate cancer-derived 
SPOP mutants including Y87C, F102V, W131G, and 
F133L, which are located in its substrate-recognizing 
MATH domain, failed to bind to and promote HDAC6 
degradation (Figure 5). Moreover, HDAC6 expression 
levels are elevated in SPOP-deficient cells. However, 
it warrants further in-depth studies to explore whether 
cancer cells with SPOP-mutant genetic status are more 
sensitive to HDAC6 specific inhibitors due to elevated 
HDAC6 protein abundance.
Taken together, this study identified the upstream 
regulator Cullin 3SPOP as a physiological E3 ubiquitin ligase 
for HDAC6. As SPOP is frequently mutated in several 
cancers, which might lead to a high level of HDAC6 and 
could alter the sensitivity to HDAC6 specific inhibitors, 
we envision that our studies may offer a potential novel 
therapeutic strategy to treat SPOP-mutant cancer patients 
with HDAC6 selective inhibitors.
MATERIALS AND METHODS
Cell cultures
293T, 293, 293FT, HCT116, HT29, DLD1, 
WM2664, and HeLa cells were cultured in DMEM 
medium (Life Technologies, CA) containing 
10% fetal bovine serum (FBS), 100 units of penicillin 
and 100 mg/ml streptomycin. PC3 and DU145 cells 
were cultured in RPMI 1640 medium (Corning, NY) 
containing 10% FBS, 100 units of penicillin and 
100 mg/ml streptomycin.
Plasmids
Myc-Cullin 1, Myc-Cullin 2, Myc-Cullin 3, Myc-
Cullin 4A, Myc-Cullin 4B, Myc-Cullin 5, Flag-SPOP 
WT, Flag-SPOP Y87C, Flag-SPOP F102C, Flag-SPOP 
W131G, pGEX-4T-1-SPOP, Flag-Keap1, Flag-COP1, 
shScramble, shCullin 3, shSPOP, and His-ubiquitin 
constructs were described previously [28]. Myc-Cullin 
7 construct was a gift from Dr. James A. DeCaprio 
(Dana-Farber Cancer Institute). KLHL2 and KLHL3 
constructs were kindly offered by Dr. Shinichi Uchida 
(Tokyo Medical and Dental University). KLHL12 and 
KLHL37 constructs were purchased from addgene. 
Flag-SPOP F133L, Flag-SPOP F133V, Flag-PLZF, Flag-
HDAC6 and HA-HDAC6 and deletion degron mutants 
were generated in this study.
Cell transfection and virus infection
When cells were at 80% confluence, we performed 
the transiently transfection with indicated constructs 
using Lipofectamine in Opti-MEM medium (Invitrogen). 
After 36 hours (h) transfection, cells were harvested 
and lysed in EBC buffer (50 mM Tris pH 7.5, 120 mM 
NaCl, 0.5% NP40) supplemented with protease inhibitors 
(Roche) and phosphatase inhibitors (Calbiochem) for 
immunoprecipation or immunoblot analysis.
293FT cell line was used for packaging and 
amplifying lentivirus. The medium containing viruses 
were collected at 48 hours and 72 hours after transfection. 
After filtering through 0.45 µM filters, viruses were used 
to infect cells in the presence of 4 μg/mL polybrene 
(Sigma-Aldrich). 48 hours post-infection, cells were split 
and selected using 1 μg/mL puromycin (Sigma-Aldrich) 
for three days to eliminate the non-infected cells before 
harvesting.
Antibodies and reagents
Anti-HDAC6 (7612), mouse monoclonal anti-
Myc-Tag (2276), rabbit polyclonal anti-Myc-Tag 
antibody (2278), anti-Cullin 3 (2759), anti-LC3-B 
(2775), EMT antibody sampler kit (9782), anti-Ac-
α-Tubulin (5335) and anti-GST (2625) antibodies 
were purchased from Cell Signaling. Anti-TRIM24 
(TIF1α, SC-271266), anti-Cullin 1 (SC-11384), anti-
HA antibody (SC-805), anti-Tubulin (SC-73242) 
and anti-p27 (SC-527) antibodies were purchased 
from Santa Cruz. Anti-SPOP antibody (16750-1-AP) 
was purchased from Proteintech. Anti-GFP (8371-2) 
antibody was purchased from Clontech. Polyclonal anti-
Flag antibody (F7425), monoclonal anti-Flag antibody 
(F-3165, clone M2), anti-vinculin antibody (V-4505), 
peroxidase-conjugated anti-mouse secondary antibody 
(A-4416), peroxidase-conjugated anti-rabbit secondary 
antibody (A-4914), anti-HA agarose beads (A-2095) 
and anti-Flag agarose beads (A-2220) were purchased 
from Sigma. All antibodies were used in 1:1000 
dilutions in 5% non-fat milk for western blot.
MLN4924 was a kind gift from Dr. William Kaelin 
(Dana-Farber cancer institute). Bafilomycin A1 was kindly 
provided by Dr. Junying Yuan (Harvard Medical School). 
MG132 (BML-PI102-0005) was purchased from Enzo life 
science.
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Immunoprecipitation, GST pull-down assays 
and western blotting
Cells were harvested and washed once by using cold 
PBS. The cell pellets were lysed in EBC buffer (50 mM 
Tris pH 7.5, 120 mM NaCl, 0.5% NP40) supplemented 
with protease inhibitors (Roche) and phosphatase 
inhibitors (Calbiochem). The lysates were cleared 
by centrifugation and the lysates were quantified by 
Beckman Coulter DU-800 spectrophotometer (Beckman 
Coulter) using the Bio-Rad protein assay reagent (Bio-
Rad Laboratories, CA). 1 mg total lysates were incubated 
with the appropriate antibody-conjugated beads (2 µg) or 
bacterial purified GST or GST fused proteins (1 µg) for 
4 hours at cold room. Immunocomplexes or GST pull-
down products were washed four times with NETN buffer 
(20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, and 
0.5% NP-40) and were eluted by boiling for 5 minutes 
in SDS loading buffer. Bound proteins were resolved by 
SDS-PAGE and immunoblotted with indicated antibodies.
Colony formation assays
HCT116 cells with stably expressing shScramble, 
shSPOP, shHDAC6 or in combination of shSPOP and 
shHDAC6 were plated in 6-well culture dishes at a density 
of 1000 cells/well and allowed to growth undisturbed for 
10 days. Cells were stained with crystal violet and the 
colony numbers were counted.
In vitro scratch assay
HCT116 cells were plated in 6-well culture dishes. 
The cell monolayer was scraped in a straight line with 
a P200 pipet tip. Photographs of the scratch were taken 
at 0 h and 48 h. Gap width at 0 h was set to 1. Gap 
width analysis was performed with ImageJ software. 
Measurements were taken at multiple defined sites (> 6) 
along the scratch. Each scratch was given an average of all 
measurements. Data are expressed as the average of three 
independent experiments.
Cell migration assay
5× 104 HCT116 cells was plated in an 8-μm, 24-well 
plate chamber insert (Corning Life Sciences, catalog no. 
3422) with 100 μL serum-free medium at the top of the 
insert and DMEM medium (Gibco) containing 10 % FBS 
(500 μL) at the bottom of the insert. Cells were incubated 
for 24 h and fixed with 4% paraformaldehyde for 15 min. 
After washing with PBS, cells at the top of the insert were 
scraped with a cotton swab. Cells adherent to the bottom 
were stained with 0.5% crystal violet blue for 15 min and 
then washed with double-distilled H2O. The positively 
stained cells were counted in eight random fields under 
the microscope, and the average value of eight fields was 
expressed. All assays were performed in triplicate.
Statistical analysis
Student t tests was used to evaluate significance 
between groups all other data, and p-values indicated. 
Error bars represent standard deviation. *p < 0.05 indicates 
significance.
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